Merck shared safety and efficacy results of MK-1084; either as monotherapy or in combinations, it demonstrated a manageable safety profile.
Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers
Where Today's News Shapes Tomorrow
February 15, 2026
Headlines
